BSK Investment
VC Fund
Seoul, South Korea
BSK Investment is a private equity investment company that invests in unlisted companies.
- Total investments:
- 50
- Last investment:
- Lead investor:
- 10%
Last updated:
For AI agents: llms.txt
Industries BSK Investment invests in
Stages BSK Investment invests in
Countries BSK Investment invests in
Round sizes
Round size
- Series A
- $2.1M–$57M
- Series B
- $4.8M–$26M
- Series C
- $13M–$24M
Investment Focus
Industry
- Biotechnology 11 (22%)
- Software 8 (16%)
- Health Care 7 (14%)
- Artificial Intelligence 7 (14%)
- Information Technology 6 (12%)
Stage
- Series A 19 (38%)
- Series B 14 (28%)
- Series C 8 (16%)
- Seed 5 (10%)
- Venture - Series Unknown 3 (6%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
FNCT Biotech
|
FNCT Biotech develops antibody therapeutics for treating idiopathic pulmonary fibrosis (IPF). To create antibodies that target the underlying cause of IPF, the company's platform uses genetic engineering, providing patients with this medical need with a new treatment option. | $14M / Series B / Jun 16, 2026 | |
BOS Semiconductors
|
BOS Semiconductors is a fabless semiconductor firm specializing in automotive-grade System-on-Chip (SoC) solutions and high-performance computing platforms. Its technologies support advanced driver assistance, autonomous driving, and centralized in-vehicle computing systems. | $60.3M / Series A / Feb 23, 2026 | |
Sionic AI
|
Sionic AI is an information technology company that offers customized artificial intelligence platform services for business enterprises. It allows companies to design, manage, and utilize tailored AI services for business development and management. | $17M / Series A / Dec 01, 2025 | |
AITRICS
|
AITRICS delivers AI-powered medical software designed to support clinicians in detecting and preventing critical patient deterioration. The company’s core product, AITRICS‑VC (VitalCare), continuously monitors data from electronic medical records (EMRs), including vital signs, lab tests, consciousness levels, and other relevant clinicalmeasurements to predict adverse events such as sepsis, cardiac arrest, unexpected ICU transfers, or mortality several hours before they occur.AITRICS-VC operates in real time, delivering risk scores and alerts to clinicians to enable earlier intervention and better resource allocation in hospital settings. The platform has been certified by the relevant regulatory authority in its home country and is classified as an “innovative medical device,” reflecting regulatory recognition of its predictive-analytics capabilities. In addition to monitoring and prediction, AITRICS engages in ongoing clinical validation and research; it publishes studies in peer-reviewed journals and presents its work in international AI conferences, indicating a commitment to evidence-based development and transparency in performance. | $23.8M / Series C / Dec 01, 2025 | |
Connecteve
|
Connective is a robotics company that develops artificial intelligence-based artificial joint surgery robots. | $9.7M / Series A / Feb 19, 2025 | |
ProtoPie
|
Prototyping interactions as easy as pie ProtoPie is an easy but powerful software that allows designers and engineers to plan, communicate, and demonstrate an interactive mobile product. Build a sophisticated prototype without any coding, but leveraging all the native mobile device features. The powerful capabilities are already recognized andadopted by the global top brands and such as Google, Microsoft, R/GA, and Ideo. | $21M / Series B / Jan 22, 2025 | |
|
FNCT Biotech
|
FNCT Biotech develops antibody therapeutics for treating idiopathic pulmonary fibrosis (IPF). To create antibodies that target the underlying cause of IPF, the company's platform uses genetic engineering, providing patients with this medical need with a new treatment option. | $4.2M / Series A / Jan 20, 2025 | |
Panmnesia
|
Panmnesia is a Korean chip startup. It is focused on developing intellectual property around a technology, which allows big data center operators to pool devices such as AI accelerator chips, processors, and memory. | $57M / Series A / Nov 19, 2024 | |
AIRS Medical
|
AIRS Medical is an MRI reconstruction software service provider. | $19.5M / Series C / Jul 10, 2024 | |
|
Stack
|
Stack specializes in the manufacturing of stacked piezoelectric ceramic actuators. The company also specializes in the blending and creation of essential raw materials required for the production of piezoelectric ceramic elements. The core product of Stack is the piezoelectric actuator that offers enhanced performance in a more compact sizecompared to traditional piezoelectric elements. Stacked piezoelectric actuators allow for more accurate regulation of gas and liquid input quantities utilized in semiconductor manufacturing. Moreover, this product is employed in the production of solder balls, which are crucial components of high-value semiconductor substrates like BGA (Ball Grid Array). Furthermore, stacked piezoelectric actuators can be utilized in the domain of energy harvesting,a vital technology in renewable energy generation. In this context, Stack is persistently advancing high-precision products and is currently engaged in research on piezoelectric actuators for autonomous driving. | $3M / Seed / Jul 09, 2024 | |
| See all 50 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does BSK Investment invest in?
BSK Investment invests primarily in Biotechnology, Software and Health Care startups, most often at Series A and Series B stage. Most of the 50 investments tracked by Shizune back companies in South Korea. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is BSK Investment's check size?
BSK Investment typically joins rounds of $2.1M–$57M at Series A, $4.8M–$26M at Series B and $13M–$24M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds BSK Investment participates in.
When did BSK Investment last invest?
The most recent investment recorded for BSK Investment closed in Jun 2026. Shizune tracks 50 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
